Smith & Nephew PLC (SN.L)
|Market Cap (Mil.):||£8,862.72|
|Shares Outstanding (Mil.):||893.54|
LONDON - A novel spray-on skin treatment consisting of living cells made by Smith & Nephew, which is designed to work with the body’s own cells to help heal leg ulcers, has failed in a late-stage clinical trial.
* Shares fall 1.2 percent (Adds analyst comments, shares)
LONDON, Oct 13 - A novel spray-on treatment consisting of living cells made by Smith & Nephew, which is designed to work with the body's own cells to help heal leg ulcers, has failed in a late-stage clinical trial.
* Second phase 3 study in European Union, which is expected to report in 2016, will continue while programme analysis is completed Source text for Eikon: Further company coverage:
* Announces an intended ratio change to its nyse-listed american depositary receipt ("ADR") programme
* Seen as possible threat to Shire's agreed sale to AbbVie
LONDON, Sept 23 - Britain's top shares fell on Tuesday, dragged down by healthcare shares as new U.S. tax rules dented the takeover appeal of companies such as Shire and AstraZeneca.
Sept 4 - London-based medical device maker Smith & Nephew PLC has agreed to pay $11.3 million to settle allegations that it sold the U.S. government devices it claimed were U.S.-made but actually came from Malaysia.
LONDON, Aug 1 - Financial stocks underperformed as Britain's top equity index fell to a three-week low on Friday, while weak UK manufacturing data also weighed on the market.
LONDON - Smith & Nephew (S&N), Europe's largest maker of artificial joints, expects continued deal-making in the medical technology sector but has not come under pressure from investors to sell out, its chief executive said on Friday.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
"The Economy Matters" Report for SNN: the economy's impact on SNN's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports
Smith & Nephew PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.